C. Light Technologies, a new neurotech and AI company that uses retinal eye-tracking to research neurodegeneration and therapeutic efficacy, announced the appointment of Lon Dowell to the position of Chief Commercial Officer (CCO). 

Mr. Dowell brings more than 30 years of experience in strategic planning, operations, and leadership for global medical device companies, including Zeiss, Leica, and Topcon, among others. As CCO, Mr. Dowell will lead the company’s commercial strategy including marketing and sales, as well as build business relationships with research organizations, clinicians, and pharma. He will collaborate on the assessment of partnership opportunities to optimize the value of C. Light Technologies’ business in the neurodegenerative and ophthalmic markets. 

“Lon brings extensive commercial experience and a unique perspective on multi-modal imaging and interoperability. We are excited that he has joined our growing team to greatly enhance our commercialization efforts,” CEO and Founder Christy Sheehy, PhD, said in a company news release.

“C. Light Technologies has established a revolutionary eye tracking technology to better understand fixational eye movement that can quickly interpret scientific discovery for potential new therapies,” said Mr. Dowell. “With Christy’s leadership, technology, and market entry, we will provide an exciting foundation from which to grow the business. I am excited to join C. Light Technologies, and I look forward to working together on efforts that will ultimately result in greater awareness for patients in need.”

About C. Light

C. Light is a neurotech and AI company that uses retinal eye-tracking to research neurodegeneration and therapeutic efficacy, a fundamentally different approach to eye tracking from other technologies on the market which measure pupil movement. Paired with AI, the biomarker platform can transform how we assess neurological diseases. 

C. Light closed a >$3 million seed round in 2021, led by Creative Ventures with major investor Yamaha Motor Ventures. The company has won two grants from the NIH and have been awarded an investment from the Alzheimer’s Drug Discovery Foundation to study fixational changes in Mild Cognitive Impairment (MCI). Additionally, C. Light has partnered with UCSF for Multiple Sclerosis research and UPMC for concussion recovery research. Most recently, they were selected for the Summer 2021 NASDAQ Milestones Makers Program.